Cowen Sees High Probability of Positive Data ASH at from Fate Therapeutics (FATE)

Go back to Cowen Sees High Probability of Positive Data ASH at from Fate Therapeutics (FATE)

Fate Therapeutics (FATE) Tops Q3 EPS by 6c

November 3, 2015 4:28 PM EST

Fate Therapeutics (NASDAQ: FATE) reported Q3 EPS of ($0.24), $0.06 better than the analyst estimate of ($0.30). Revenue for the quarter came in at $1 million versus the consensus estimate of $430 thousand.

For earnings history and earnings-related data on Fate Therapeutics (FATE) click here.

... More